Powering Moderna’s digital biotechnology platform to develop new vaccines

In a pandemic, speed to market matters and Moderna was able to complete the sequence for its mRNA COVID-19 vaccine in just 2 days using machine learning built on AWS. The first clinical batch was released just 25 days later. Artificial intelligence (AI) algorithms enable drug development from rapid experimentation cycles to help design mRNA and DNA sequences to the automation of quality control analyses, saving hours of manual review of improvements across production processes and logistics. mRNA science has applicability beyond just one application, and Moderna is rapidly expanding into other infectious disease targets and modalities like oncology and autoimmune disease—using the flexible, programmable nature of mRNA, powered by machine learning, to revolutionize how diseases are treated.